Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
07/19/20174:25PMPRNUSTheravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patie...
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) These Data, Combined with Positive Results from Two Phase 3 Efficacy Studies, Support NDA Filing Planned for Fourth Quarter of 2017 PR Newswire... More...>>
07/19/20174:25PMPRNUSTheravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patie...
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) These Data, Combined with Positive Results from Two Phase 3 Efficacy Studies, Support NDA Filing Planned for Fourth Quarter of 2017 PR Newswire... More...>>
07/19/20177:30AMPRNUSMylan to Report Second Quarter 2017 Financial Results on Aug. 9, 2017
Mylan to Report Second Quarter 2017 Financial Results on Aug. 9, 2017 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 19, 2017 HERTFORDSHIRE, England and PITTSBURGH, July 19, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Wednesday, Aug... More...>>
07/13/20175:02PMPRNUSFDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab Vote Marks First Proposed Biosimilar Trastuzumab to be Recommended by the Committee PR Newswire HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, July 13, 2017 HERTFORDSHIRE, England and PITTSBURGH... More...>>
06/10/20171:30PMPRNUSMylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions Data Show Comparable Efficacy, Safety and Immunogenicity to Lantus® in Type 1 and Type 2 Diabetes Patients PR Newswire HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 10, 2017 HERTFORDSHIRE... More...>>
06/07/20175:26PMPRNUSMylan to Present at Goldman Sachs 38th Annual Global Healthcare Conference
Mylan to Present at Goldman Sachs 38th Annual Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 7, 2017 HERTFORDSHIRE, England and PITTSBURGH, June 7, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) a leading global pharmaceutical company, today announced that the Company will present... More...>>
06/02/20178:00AMPRNUSMylan Launches Generic Azilect® Tablets
Mylan Launches Generic Azilect® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed drug... More...>>
06/02/20177:30AMPRNUSMylan Launches Generic Reclast® Injection
Mylan Launches Generic Reclast® Injection PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis... More...>>
05/23/20179:15AMPRNUSTheravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase... More...>>
05/23/20179:15AMPRNUSTheravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase... More...>>
05/17/20178:30AMPRNUSTheravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS Presentations Will Include Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies PR Newswire DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 17, 2017 DUBLIN and HERTFORDSHIRE... More...>>
05/16/20174:38PMPRNUSMylan to Present at UBS Global Healthcare Conference
Mylan to Present at UBS Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 16, 2017 HERTFORDSHIRE, England and PITTSBURGH, May 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company will present at the UBS Global Healthcare Conference on Monday, May 22... More...>>
05/16/201710:15AMPRNUSMylan Honors National Women's Health Week to Empower Women to Take Control of Their Health
Mylan Honors National Women's Health Week to Empower Women to Take Control of Their Health PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 16, 2017 HERTFORDSHIRE, England and PITTSBURGH, May 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today joins the U.S. Department of Health and Human Services (HHS... More...>>
05/10/20177:30AMPRNUSMylan Reports First Quarter 2017 Results
Mylan Reports First Quarter 2017 Results First Quarter Total Revenues Increase 24% PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 10, 2017 HERTFORDSHIRE, England and PITTSBURGH, May 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter ended March 31, 2017... More...>>
05/01/20179:00AMPRNUSMylan Nominates Sjoerd Vollebregt for Election to Board of Directors
Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors Directors Douglas Leech, Joseph Maroon and Rodney Piatt to Retire from Board PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 1, 2017 HERTFORDSHIRE, England and PITTSBURGH, May 1, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
04/27/20174:45PMPRNUSMylan to Report First Quarter 2017 Financial Results on May 10, 2017
Mylan to Report First Quarter 2017 Financial Results on May 10, 2017 PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, April 27, 2017 HERTFORDSHIRE, England, and PITTSBURGH, April 27, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Wednesday... More...>>
04/20/20171:39PMPRNUSMylan Launches Generic Trilafon Tablets
Mylan Launches Generic Trilafon Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017 HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg, a generic version of the... More...>>
03/31/20175:11PMPRNUSMylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen® Au...
Mylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen® Auto-Injector PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 31, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
03/29/20174:30PMPRNUSMylan Completes Acquisition of Cold-EEZE® Brand
Mylan Completes Acquisition of Cold-EEZE® Brand PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the successful acquisition of the global rights to the Cold-EEZE® brand cold remedy line... More...>>
03/29/20171:16PMPRNUSMylan Comments on Generic Advair Diskus® Abbreviated New Drug Application
Mylan Comments on Generic Advair Diskus® Abbreviated New Drug Application PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today commented on the status of its abbreviated new drug application (ANDA... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20170722 18:38:27